BLSM - BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti- Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S- Positive NSCLC at IASLC 2026 World Conference on Lung Cancer
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.